Synthetic peptides derived from midkine enhance plasminogen activator activity in bovine aortic endothelial cells.
Chemically synthesized human midkine enhanced plasminogen activator activity and decreased its inhibitor levels in bovine aortric endothelial cells. These activities were preserved in the C-terminal half, but not in the N-terminal half of the midkine molecule. Furthermore, a synthetic peptide of 43 amino acids designated as "C-domain", which formed the compact structure held by two disulfide bonds in the C-terminal half, mimicked intact midkine. Chemically synthesized C-domain of pleiotrophin (43 amino acids), which was 53% identical to midkine C-domain in amino acid sequence, expressed the similar activities. These 43 amino acid peptides are, so far, the shortest peptide able to enhance the fibrinolytic activities of the endothelial cells.
Kojima
S
S
Laboratory of Gene Technology and Safety, Tsukuba Life Science Center, Institute of Physical and Chemical Research (RIKEN), Ibaraki, Japan.
Inui
T
T
Kimura
T
T
Sakakibara
S
S
Muramatsu
H
H
Amanuma
H
H
Maruta
H
H
Muramatsu
T
T
D000595:Amino Acid Sequence; D000818:Animals; D001011:Aorta; D002352:Carrier Proteins / Q000737:chemistry / Q000494:pharmacology*; D002417:Cattle; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology*; D004789:Enzyme Activation; D006801:Humans; D007700:Kinetics; D000078792:Midkine; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism*; D017433:Protein Structure, Secondary
D002352:Carrier Proteins; D016207:Cytokines; D010446:Peptide Fragments; D017395:Plasminogen Activator Inhibitor 1; D000078792:Midkine; D010960:Plasminogen Activators